GFR

(redirected from Growth factor receptor)
Also found in: Wikipedia.
Category filter:
AcronymDefinition
GFRGlomerular Filtration Rate (renal system)
GFRGeneral Financial Rules (various organizations)
GFRGas-Cooled Fast Reactor (nuclear reactor)
GFRGrand Funk Railroad (band)
GFRGrowth Factor Receptor
GFRGlobal Formula Racing
GFRGuaranteed Frame Rate
GFRGlass Fiber Reinforced (molded plastics)
GFRGainesville Fire Rescue (Gainesville, Florida)
GFRGrim File Reaper
GFRGreat American Financial Resources, Inc.
GFRGefreiter (German)
GFRGesellschaft für Regelungstechnik und Energieeinsparung mbH
GFRGeneric Fill Rate (medications)
GFRGeneric Fill Rate (Medicaid prescriptions)
GFRGround Fault Relay
GFRGovernment Flight Representative
GFRGroupe Fonciere des Régions (French)
GFRGesellschaft für Resourcenschutz (German: Society for Resource Protection)
GFRGovernment Furnished Representative
GFRGas Facility Reporting
GFRGround and Flight Risk
GFRGrain Filling Rate
GFRGap Filler Radar
GFRGeneral Functional Requirements
GFRGeophysical Field Report (Canada)
GFRGeneral Flight Rules
GFRGerman Family Rockers (gaming clan)
GFRGas Filled Rectifier
GFRGraduate French Program
GFRGay for Real
GFRGrunting, Flaring and Retracting (infant respiration)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Jose Baselga, Executive Vice President, Oncology R&D said: "Today's positive results show that Tagrisso provides an unprecedented survival outcome versus previous standard-of-care epidermal growth factor receptor tyrosine kinase inhibitors, reaffirming Tagrisso as the 1st-line standard-of-care for EGFR-mutated metastatic non-small cell lung cancer."
Jose Baselga, executive vice president of Oncology Research & Development at Astra said: "Today's positive results show that Tagrisso provides an unprecedented survival outcome versus previous standard-of-care epidermal growth factor receptor tyrosine kinase inhibitors, reaffirming Tagrisso as the 1st-line standard-of-care for EGFR-mutated metastatic non-small cell lung cancer."
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.
et al., "Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma", Hepatology, 2014, 59, 1427-1434.
(1.) Wolff AC, Hammond MEH, Allison KH, et al: Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update.
Browse Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market by Drug Classes (Angiogenesis Inhibitors - Avastin, Cyramza; Epidermal Growth Factor Receptor Blockers - Tarceva, Gilotrif, Iressa; Folate Antimetabolites - Alimta; Kinase Inhibitors - Xalkori, Zykadia; Microtubule Stabilizers - Abraxane, Docetaxel; and PD-1/ PD-L1 Inhibitors - Opdivo, Keytruda), and Clinical Pipeline Analysis of Phase 1, 2 and 3 Drugs (Avelumab, MPDL3280A, MEDI4736, Abemaciclib) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/non-small-cell-lung-cancer-therapeutics-market/
Fibroblast growth factor receptor 1 (FGFR1) has been identified as one of the emerging molecular targets for the treatment of SCC of the lung,[sup][3],[4],[5] and several early-phase clinical trials of FGFR1 inhibitors are currently being undertaken in NSCLC.[sup][6],[7],[8] Alterations of the FGFR gene have been recognized in many epithelial malignancies, including amplifications in gastric, breast, oral squamous cell, ovarian, and bladder carcinomas,[sup][9],[10] and more recently in squamous NSCLC.
The highly expressed growth factor receptor genes, meanwhile, were platelet-derived growth factor receptor-like protein, platelet-derived growth factor receptor (beta polypeptide), autocrine motility factor receptor, transforming growth factor beta type 2 receptor, epidermal growth factor receptor, and insulin-like growth factor 2 receptor (IGF2R).
Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer.
[11.] Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.
Major role in growth and differentiation for a variety of malignant and normal cells retinoids are regarded to have an important function.They are known to play a major role in regulatinggrowth and differentiation of a variety of normal and malignant cells.11Topical all trans RA treatment caused an increase in the number of living cell layers in the epidermis of both human and mouse.1213It has been reported that retinoic acid treatmentresults in expression of post-transcriptional elevation in epidermal growth factor receptors (EGF R).14The epidermal growth factor receptor (EGFR) is the cell surface receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands.
Since its discovery, the epidermal growth factor receptor (EGFR) continues to be the subject of myriad investigations in cancer signalling.